At Johnson & Johnson Innovative Medicine, we are relentlessly driven to make a difference in the lives of patients and families impacted by immune-mediated diseases. This commitment includes autoantibody diseases, which are caused by pathogenic antibodies made by one’s own body that attack critical organs and tissues.
Our research has the potential to help the estimated 240 million people worldwide who suffer from autoantibody diseases, many of which have no safe, effective treatments. Johnson & Johnson aims to revolutionize care for patients with a novel therapy that reduces pathogenic antibodies while safely maintaining immune function, furthering our goal to redefine treatments for immune diseases.
In pregnancy, maternal antibodies (also known as alloantibodies), can attack the organs and tissues of a developing baby with potentially devastating consequences, including fetal death.
Learn more about autoantibodies on
JNJ.com